You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Genzyme’s new MS therapy OK’d by European officials

European regulators Tuesday put their stamp of approval on Genzyme’s multiple sclerosis drug Lemtrada, giving the Cambridge biotechnology company a second MS treatment for the overseas market only weeks after its first won approval there.

The move vindicated French drug maker Sanofi SA’s decision to pay $20.1 billion for Genzyme in 2011, a deal that hinged on the potential of Lemtrada, then an experimental therapy.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week